Cutler Group’s Genocea Biosciences, Inc. GNCA Stock Holding History

Cutler Group’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-900	Closed	-$1K	–	6066
2022 Q1	$1K	Hold	900	–	–	﹤0.01%	5199
2021 Q4	$1K	Hold	900	–	–	﹤0.01%	5277
2021 Q3	$1K	Hold	900	–	–	﹤0.01%	5584
2021 Q2	$2K	Hold	900	–	–	﹤0.01%	5170
2021 Q1	$2K	Hold	900	–	–	﹤0.01%	5095
2020 Q4	$2K	Hold	900	–	–	﹤0.01%	4329
2020 Q3	$2K	Buy	+900	New	+$2.36K	﹤0.01%	4209
2020 Q1	–	Sell	-100	Closed	–	–	5043
2019 Q4	$0	Hold	100	–	–	﹤0.01%	4980
2019 Q3	$0	Buy	+100	New	+$341	﹤0.01%	5065
2017 Q4	–	Sell	-88	Closed	-$1K	–	6481
2017 Q3	$1K	Sell	88 -512	-85%	-$19.4K	﹤0.01%	5693
2017 Q2	$25K	Buy	+600	New	+$28.9K	﹤0.01%	3207

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Cutler Group's GNCA Position: Q2 2022 in Review

Cutler Group sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 900 shares — an estimated $1K sold.

Cutler Group first reported a position in GNCA in Q2 2017 and held it in 11 quarters. The position peaked at $25K in Q2 2017. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

Cutler Group reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
Cutler Group sold 900 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $1K.
Cutler Group first reported a position in Genocea Biosciences, Inc. in Q2 2017 and held it in 11 quarters.
Cutler Group's Genocea Biosciences, Inc. position peaked at $25K in Q2 2017.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.